Morgan Stanley lowered the firm’s price target on Globus Medical to $53 from $60 and keeps an Equal Weight rating on the shares after Globus reported Q3 revenue that included $102M in NuVasive’s September revenue. Management maintained full-year EPS guidance at $2.30 while FY23 revenue is now expected to be up 7% on a pro-forma basis, noted the analyst. The firm’s multiple applied to its FY24 EBITDA estimate is “a discount to profitable MedTech peers given risks inherent with the NuVasive merger,” thought this discount “could narrow over time,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMED:
- Globus Medical price target lowered to $53 from $58 at Truist
- Globus Medical backs FY23 EPS view $2.30, consensus $2.32
- Globus Medical reports Q3 EPS 57c, consensus 54c
- Globus Medical Reports Third Quarter 2023 Results
- GMED Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Questions or Comments about the article? Write to editor@tipranks.com